IASLC Newsletter - May 2018

With this corner, I would like to draw your attention to our new strategic plan.

The Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) have awarded a pair of two-year grants, generously funded in part by Bristol-Myers Squibb, to support research that will hopefully help lung cancer patients lead longer, healthier lives.

Significant disparities in the quality of end-of-life lung cancer care were found among racial-ethnic minorities, with higher odds of experiencing potentially preventable medical encounters during end-of-life as compared with non-Hispanic whites.

IASLC Newsletter - April 2018

In my first president’s corner in November 2017, I discussed the IASLC's strategic plan, an initiative that will precisely define the organization's objectives and the time frame that will be necessary in order to achieve them.

Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial (1) presented at the ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.